Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, September 1999, p. 665-670, Vol. 6, No. 5
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Low Levels of Antigenic Variability in
Fluconazole-Susceptible and -Resistant Candida albicans
Isolates from Human Immunodeficiency Virus-Infected Patients with
Oropharyngeal Candidiasis
Jose L.
Lopez-Ribot,1,*
Robert K.
McAtee,1
William R.
Kirkpatrick,1
Roberto
La
Valle,2 and
Thomas F.
Patterson1
Department of Medicine, Division of
Infectious Diseases, The University of Texas Health Science Center at
San Antonio, San Antonio, Texas,1 and
Department of Bacteriology and Medical Mycology, Istituto
Superiore di Sanità, Rome, Italy2
Received 8 February 1999/Returned for modification 5 April
1999/Accepted 17 May 1999
 |
ABSTRACT |
Three serial isolates of Candida albicans were obtained
by direct swab or by oral saline rinses from each of five human
immunodeficiency virus-infected patients with recurrent oropharyngeal
candidiasis. Genotyping techniques confirmed the presence of a
persistent strain in multiple episodes from the same patient, which was
different from the strains isolated from other patients. Fluconazole
susceptibility was determined by both an agar dilution method and the
National Committee for Clinical Laboratory Standards macrobroth
procedure. In four of these patients the strains developed fluconazole
resistance, and in one patient the strain remained susceptible. The
different isolates were propagated as yeast cells on a synthetic
medium, and their cell wall proteinaceous components were extracted by treatment with
-mercaptoethanol. Protein and mannoprotein components present in the extracts were analyzed by electrophoresis,
immunoblotting, and lectin-blotting techniques. The analysis showed a
similar composition, with only minor qualitative and quantitative
differences in the polypeptidic and antigenic patterns associated with
the cell wall extracts from serial isolates from the same patient, as
well as those from different strains isolated from different patients.
Use of monospecific antibodies generated against two immunodominant
antigens during candidiasis (enolase and the 58-kDa fibrinogen-binding
mannoprotein) demonstrated their expression in all isolates tested.
Overall, the antigenic makeup of C. albicans strains
remained constant during the course of infection and was not affected
by development of fluconazole resistance. In contrast to previous
reports, the low degree of antigenic variability observed in this study
may be due to the fact that the isolates were obtained from a highly
homogeneous population of patients and to the uniformity in techniques
used for the isolation, storage, and culture of the different strains,
as well as extraction methodologies.
 |
INTRODUCTION |
Although the cell wall of
Candida albicans was previously considered an almost inert
structure, today its importance is well established in almost every
aspect of the biology and pathogenicity of this fungus (10,
11). The cell wall of C. albicans is a complex mosaic
of polysaccharides and proteins in which mannoproteins constitute the
major antigens and host recognition molecules. A number of studies from
different laboratories have demonstrated a high degree of complexity
associated with the protein and mannoprotein composition of the cell
wall of C. albicans (reviewed in reference 11). Also, the expression, chemical characteristics,
and physiological properties of proteins and mannoproteins present in
the C. albicans cell wall appear to be dependent on multiple
environmental (i.e., growing conditions, nutritional factors,
temperature) as well as organism (strain, morphology, phenotypic
switching)-related factors (1, 5, 6, 8, 12, 13, 16, 18, 26, 30,
40-42, 49, 50). Thus, the C. albicans cell wall
appears to be a highly dynamic structure that exhibits the ability to differentially express constituents useful for switching between commensal and pathogenic lifestyles and for modulating and/or evading
immune host defenses (12, 32).
Cell wall proteins and mannoproteins of C. albicans are
major elicitors of the host immune response, and our increasing
knowledge of the identity and expression of these components may assist in the development of novel approaches for the management of the different forms of candidiasis (32, 33). Characterization of
cell wall antigens and anti-cell wall antibodies may provide the basis
for developing improved methods for the serodiagnosis of candidiasis
(21, 32, 43). In addition, in recent years, there has been
increasing evidence that some Candida-specific antibodies
can be immunoprotective during infection, at both the mucosal and the
systemic levels, thus suggesting the viability of an immunotherapy
and/or vaccine approach for the treatment and management of candidiasis
(7, 17, 33, 35). In the present study, in which extrinsic
variables were minimized, we present evidence for low levels of
antigenic variability associated with cell wall antigens of C. albicans clinical isolates obtained during successive episodes of
oropharyngeal candidiasis (OPC) from human immunodeficiency virus
(HIV)-infected patients, including isolates that developed resistance
to fluconazole.
 |
MATERIALS AND METHODS |
Organisms and culture conditions.
Three serial isolates of
C. albicans were obtained by direct swab or by oral saline
rinses from five HIV-infected patients with recurrent OPC enrolled in a
longitudinal study to assess significance of fluconazole resistance.
Patients were treated initially with fluconazole at 100 mg/day and
increased doses up to 800 mg/day if necessary for clinical resolution
if development of resistance was detected (44). The identity
of the clinical isolates as C. albicans was confirmed by
both biochemical (API 20C; Analytab Products) and microbiological (germ
tube formation in serum-containing medium and color in CHROMagar
Candida) procedures. Initial plating of isolates and preliminary
assessment of drug susceptibility were performed by a fluconazole agar
dilution method (37, 38). Briefly, dilutions of oral samples
are added to plates containing solid medium with or without
fluconazole, and individual colonies are then recovered. This technique
maximizes early detection of resistant isolates (37, 38).
Fluconazole MICs for the different isolates were determined by the
National Committee for Clinical Laboratory Standards (NCCLS) broth
macrodilution procedure (36). The different isolates were
stored at room temperature as suspensions in sterile deionized water.
Table 1 lists the isolates, the patients
from which they were recovered, the elapsed time of isolation, and the
fluconazole MICs for the isolates.
Strain identification.
Strain identity was investigated by
karyotyping, restriction fragment length polymorphism (RFLP), and DNA
fingerprinting using the moderately repetitive probe Ca3 as previously
described (28). Briefly, chromosomes from the different
isolates were prepared in agarose plugs, separated by pulsed-field
gel electrophoresis (Bio-Rad, Hercules, Calif.), stained with ethidium
bromide, and photographed under UV light. RFLP patterns were generated
by digestion of genomic DNA with SfiI (Boehringer Mannheim,
Indianapolis, Ind.). After separation by pulsed-field gel
electrophoresis, gels were stained with ethidium bromide and
photographed. Following documentation, the materials present in the
RFLP gels were transferred to nylon membranes (Nytran; Schleicher and
Schuell, Keene, N.H.) and hybridized with a Ca3 probe radioactively
labeled by random priming (Random Primers DNA Labeling System;
GibcoBRL, Gaithersburg, Md.). The membranes were then washed and
exposed to autoradiography film (Du Pont, Wilmington, Del.). Pictures
of the gels or films were scanned by using the Adobe Photoshop program
(Adobe Systems Inc., Mountain View, Calif.). For preparation of
figures, digital images were processed with the Adobe Photoshop program.
Preparation of cell wall extracts.
The different isolates
were subcultured onto plates containing Sabouraud dextrose agar 48 h prior to propagation as blastoconidia (yeast phase) in the minimal
medium supplemented with amino acids described by Lee and colleagues
(24), for which a loopful of cells from the corresponding
plate were inoculated into a flask containing the liquid medium, and
incubated for 24 h at room temperature in an orbital shaker.
-Mercaptoethanol (
ME) was used to solubilize protein and
glycoprotein components from the walls of intact C. albicans
cells as previously described with minor modifications (27).
Briefly, cells from cultures of each isolate were independently resuspended in alkaline buffer containing 1% (vol/vol)
ME and incubated for 45 min at 37°C with gentle agitation. After treatment, the cells were sedimented, and the supernatant fluid was recovered and
centrifuged in a Millipore Ultrafree-15 centrifugal filter device
(Millipore Corp., Bedford, Mass.) for desalting and concentration (
ME extract). The total sugar contents in the different samples were
determined colorimetrically with mannose as a standard (14).
PAGE and Western blot.
Cell wall components present in the
ME extracts from the different isolates were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using
precast 4 to 15% acrylamide gradient minigels (Bio-Rad). Coomassie
staining of the proteins present in the gels, electrophoretic transfer
to nitrocellulose membranes, and indirect staining of glycoproteins
present in the membranes with concanavalin A were performed as
previously described (8). Different antibody preparations
were used as probes for immunoblotting experiments: (i) a pooled
polyclonal antiserum generated against Zymolyase and
ME cell wall
extracts from C. albicans 3153A (27), (ii) a
polyclonal antibody preparation generated against the purified 58-kDa
fibrinogen-binding mannoprotein (mp58) of C. albicans
(9), (iii) a monospecific polyclonal antiserum generated
against recombinant C. albicans enolase expressed as a
6-histidine-tagged protein in Escherichia coli (to be
described elsewhere), (iv) pooled serum samples from the same
HIV-infected patients with OPC from whom the strains were isolated, and
(v) fresh pooled oral saline rinses obtained from patients enrolled in
the study (the saline washes were centrifuged at low speed prior to
their utilization in the assay). The different antibody preparations
were diluted in 10 mM Tris-HCl buffer saline (pH 7.4), supplemented
with 0.05% Tween 20 and 1% bovine serum albumin (TBSTB buffer).
Anti-rabbit (immunoglobulin G [IgG]), anti-mouse (IgG), or anti-human
(IgG, IgM, and IgA) peroxidase-conjugated antibodies (depending on the
antibody preparation used during the primary incubation) were used as
indicator antibodies, with 4-chloro-1-naphthol as chromogenic reagent.
The gels or blots were scanned by using the Adobe Photoshop program.
For preparation of figures, digital images were processed by using the
Adobe Photoshop program.
 |
RESULTS |
Genotyping of isolates.
The identities of strains from a given
patient were confirmed by karyotyping, RFLP, and fingerprinting with
the C. albicans Ca3 probe (Fig.
1). Sequential isolates from each patient
were demonstrated to be highly related and distinct from isolates
recovered from other patients by all typing methods employed (Table 1). Minor differences in the karyotyping patterns between isolates 7 to 9 (from patient C) are suggestive of the fact that these isolates may
constitute different substrains or strain variants of the same
persistent strain rather than a completely unrelated strain. These
results indicated presence of a persistent strain in each different
patient that was associated with the initial episode and successive
relapses. They also indicated that the serial isolates from a given
patient included in the present study are genotypically similar.

View larger version (80K):
[in this window]
[in a new window]
|
FIG. 1.
Karyotype (A), RFLP analysis generated by
SfiI digestion of genomic DNA (B), and fingerprinting
analysis with the Ca3 probe (C) of C. albicans clinical
isolates recovered during three OPC episodes from HIV-infected
patients. See Table 1 for identities of isolates.
|
|
Analysis of
ME cell wall extracts from different isolates.
For all the C. albicans isolates included in the analysis,
treatment of intact cells with
ME led to the solubilization of a
complex array of cell wall proteinaceous components, exhibiting a wide
range of apparent molecular masses (from >200 to <20 kDa) when
separated by SDS-PAGE. Coomassie blue staining (Fig.
2A) allowed detection of the medium- to
low (<120-kDa)-molecular-mass proteins present in the different
extracts and revealed no major differences in the peptidic profiles
associated with the
ME extracts obtained from the different C. albicans isolates, independently of the patient from whom they
were initially isolated. In all cases, the high-molecular-mass material
(>120 kDa) was insensitive to the dye, as has been reported previously
(8). Indirect concanavalin A-peroxidase staining of the
nitrocellulose blots revealed the glyco(manno)protein nature of the
high-molecular-weight materials (HMWM) present in cell wall extracts
from all isolates (Fig. 2B). Staining with the lectin resulted in
poorly resolved patterns due to the highly glycosylated and
polydisperse nature of the HMWM. The lectin also recognized a discrete
band showing an apparent electrophoretic mobility of approximately 35 kDa present in all isolates tested. Once again, no major differences
between the different isolates were detected by the lectin blot
technique. A similar antigenic composition associated with the cell
wall extracts from the various C. albicans isolates was
further revealed by immunoblot analysis with a polyclonal antiserum
generated against a collection strain of C. albicans, which
recognizes most of the moieties present in the extract (27).
This polyclonal antiserum recognized antigenic components along the
whole spectrum of molecular masses of species present on the blots.
Reactivity included both polydisperse bands mainly in the HMWM and
discrete moieties present in the medium- to low-molecular-mass range
(Fig. 2C). These included discrete bands exhibiting electrophoretic
mobilities of approximately 29, 32, 35, 39, 45, and 48 kDa, together
with highly reactive components of apparent molecular masses between 55 and 80 kDa.

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 2.
Electrophoretic profiles of total proteinaceous
components present in ME extracts from C. albicans
clinical isolates. The materials present in the extracts were separated
by SDS-PAGE and stained with Coomassie blue (A) or subsequently
transferred to nitrocellulose membranes and reacted with concanavalin
A-peroxidase (B) or with a pooled polyclonal antiserum preparation
(diluted 1:2,000 in TBSTB) generated against cell wall components of
the C. albicans type strain 3153A (C). The amount applied to
each well was 50 µg (A and C) or 25 µg (B) of material, expressed
as total sugar content. Lanes S, standard proteins of known molecular
masses (MM) run in parallel.
|
|
Presence of immunodominant C. albicans enolase and mp58
in the cell wall extracts of C. albicans isolates.
Immunoblot analysis of
ME extracts from all isolates tested with
monospecific antibodies generated against recombinant C. albicans enolase and the purified 58-kDa fibrinogen-binding
mannoprotein (mp58) confirmed the presence of these two highly
immunogenic moieties in the cell wall extracts from all isolates
examined (Fig. 3). As expected, in the
case of the fibrinogen-binding mannoprotein, the polyclonal antibody
preparation recognized a homologous broad band displaying an apparent
molecular mass of approximately 58 kDa in all isolates tested (Fig.
3A). When a monospecific antibody generated against recombinant
C. albicans enolase was used as a probe in the immunoblots
(Fig. 3B), strong reactivity was detected with a 48-kDa discrete band
present in the extracts from all C. albicans isolates
tested.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 3.
Immunoblot analysis with polyclonal antiserum (diluted
1:500 in TBSTB) generated against the purified C. albicans mp58 (A) and a monospecific polyclonal antiserum (diluted
1:250 in TBSTB) against recombinant C. albicans enolase (B).
Materials present in the extracts were separated by SDS-PAGE and
transferred to nitrocellulose membranes. Peroxidase-conjugated
anti-rabbit IgG (A) or anti-mouse IgG (B) (diluted 1:2,000 in TBSTB)
were used as indicator antibodies. The amount applied to each well was
50 µg of material, expressed as total sugar content. Molecular masses
(MM) of prestained standard proteins run in parallel (lanes S) are
indicated.
|
|
Presence of antibodies against cell wall proteins in serum samples
and oral saline rinses from HIV-infected patients with OPC.
Anti-Candida antibodies are present in the sera from normal
and infected individuals. A local antibody response, mainly secretion of IgA, is also induced at the mucosal level during episodes of OPC
(reviewed in reference 32). Thus, serum samples and
oral saline rinses from patients with OPC provided additional antibody preparations for the study of cell wall antigenic composition associated with the different C. albicans isolates.
Antibodies present in serum samples (Fig.
4A) recognized the polydisperse HMWM (as
expected, since antimannan antibodies are ubiquitous in human sera)
(32), as well as several well-defined medium- to
low-molecular-mass bands present in the extracts. A particularly intense labeling was observed in the region of 70 to 90 kDa, which may
represent reactivity to a cluster of candidal antigens, which includes
heat shock proteins, that are highly immunogenic (23, 25,
34). Also, among other bands, a high level of reactivity was
detected against a moiety with an apparent molecular mass of
approximately 48 kDa, which may correspond to enolase, as described above. When a preparation consisting of pooled oral saline rinses from
patients with OPC was used as a probe in the immunoblots, diffuse
reactivity was observed mainly against HMWM (Fig. 4B).

View larger version (98K):
[in this window]
[in a new window]
|
FIG. 4.
Immunoblot analysis of the materials present in the
ME extracts from the different C. albicans isolates,
using as probes pooled serum samples (diluted 1:500 in TBSTB) of the
same HIV-infected patients with OPC from whom the strains were isolated
(A) or fresh oral saline rinses (diluted 1:10 in TBSTB) from
HIV-infected patients with OPC (B). SDS-PAGE and transfer to
nitrocellulose membranes were performed as for Fig. 3. A mixture of
peroxidase-conjugated anti-human IgG, IgM, and IgA (diluted 1:500 each
in TBSTB) was used as secondary antiserum. The amount loaded in each
well was 50 µg of material, expressed as total sugar content. Lanes
S, standard proteins of known molecular masses (MM) run in parallel.
|
|
 |
DISCUSSION |
Fueled by important observations on the role of antibodies during
fungal infections (7, 32), together with the emergence of
resistance to the most common antifungal drugs currently used (45), a renewed interest in the development of novel,
immune-based strategies for the management of fungal infections,
including the different manifestations of candidiasis (7,
32), has developed. These could include both vaccination (as
immunoprophylaxis in selected at-risk patients) and immunotherapy (as
adjunctive treatment to complement antifungal-drug regimens currently
in use). However, the antigenic variability exhibited by C. albicans could severely hamper progress in the development of such
novel strategies. Characterization of common immunodominant antigens during candidiasis is essential in identification of new opportunities for immunointervention.
The present study was designed to minimize the effect of extrinsic
factors on the proteinaceous and antigenic composition of the C. albicans cell surface. First, the study included serial isolates
from successive episodes of OPC that represented the same strain for
each of the patients, as determined by a variety of genotyping
techniques. Second, we also maintained consistency in the different
techniques used for manipulation of the strains, including screening
and initial isolation, storage, culture conditions, and extraction
methodologies, since all these have been described as affecting
antigenic composition (6, 20). Third, we focused on the
protein component rather than the carbohydrate component that has been
associated with a higher degree of variability (3, 19, 20).
In doing so, we were able to demonstrate low levels of antigenic
variability among C. albicans isolates and identify proteinaceous antigens that are common to all isolates tested. Enolase
and the 58-kDa fibrinogen-binding mannoprotein (mp58) are
immunodominant antigens present in the C. albicans cell
wall, eliciting potent antibody responses during candidiasis (2, 9, 15, 29, 46-48). The present study confirmed their presence in
cell wall extracts from all isolates under investigation and provided
confirmation of their immunodominant role. Moreover, the use of serum
and oral saline rinses from patients as probes in the immunoblots
demonstrated that some of these antigens are able to elicit an antibody
response "in vivo" during infection. Interestingly, although
preliminary in nature, these experiments also demonstrated a different
antibody response to C. albicans cell wall antigens at the
mucosal and systemic levels and are indicative of the
compartmentalization of the immune response to this pathogen.
The present study combines the use of typing techniques to determine
strain identity (genotype) (39) with the analysis of cell
wall extracts to assess antigenic variability (phenotype). Despite
major genotypic differences detected between isolates recovered from
different patients, the "antigenic fingerprints" were similar, and
the analysis of cell wall components allowed characterization of
antigenic moieties common to all strains tested. Also important is the
fact that the antigenic makeup did not appear to change with
progression of infection or with development of fluconazole resistance.
This is demonstrated by the detection of virtually the same antigenic
profiles associated with matched sets of susceptible and resistant
isolates obtained in successive OPC episodes from a given patient. It
has to be noted that some of these isolates were recovered almost 1 year apart (Table 1). This is in contrast to changes in other
phenotypic properties, such as increased levels of expression of efflux
pumps or enzymes involved in the ergosterol biosynthesis, detected in
the same isolates as resistance developed (28). Since
decreased susceptibility to this antifungal agent has been associated
with increasing rates of clinical failures (4, 22, 31, 44,
45), it is precisely in these instances that the development of
immune-based therapies should prove more important in helping combat
refractory disease.
Overall, the present report describes low levels of antigenic
variability associated with components present in cell wall extracts
obtained from C. albicans clinical isolates, including fluconazole-susceptible and -resistant isolates, propagated as blastospores in a synthetic medium. These results offer new hope for
the development of novel management strategies for candidiasis that are
urgently needed.
 |
ACKNOWLEDGMENTS |
This work was supported by a grant from Pfizer Inc. and by Public
Health Service grants 1 R29 AI42401 (to J.L.L.-R.), 5 RO1 DE11381 (to
T.F.P.), and M01-RR-01346 for the Frederic C. Bartter General Clinical
Research Center.
Chromogenic medium was provided by CHROMagar Company. We thank the
Fungus Testing Laboratory at UTHSCSA for performing antifungal susceptibility testing and Antonio Cassone for helpful comments and suggestions.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Medicine, Division of Infectious Diseases, The University of Texas
Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78284-7881. Phone: (210) 567-1981. Fax: (210) 567-3303. E-mail: ribot{at}uthscsa.edu.
 |
REFERENCES |
| 1.
|
Alloush, H. M.,
J. L. López-Ribot, and W. L. Chaffin.
1996.
Dynamic expression of cell wall proteins of Candida albicans revealed by probes from cDNA clones.
J. Med. Vet. Mycol.
34:91-97[Medline].
|
| 2.
|
Angiolella, L.,
M. Facchin,
A. Stringaro,
B. Maras,
N. Simonetti, and A. Cassone.
1996.
Identification of a glucan-associated enolase as a main cell wall protein of Candida albicans and an indirect target of lipopeptide antimycotics.
J. Infect. Dis.
173:684-690[Medline].
|
| 3.
|
Barturen, B.,
J. Bikandi,
R. San Millán,
M. D. Moragues,
P. Régulez,
G. Quindós, and J. Pontón.
1995.
Variability in expression of antigens responsible for serotype specificity in Candida albicans.
Microbiology
141:1535-1543[Abstract].
|
| 4.
|
Boschman, C. R.,
U. R. Bodnar,
M. A. Tornatore,
A. A. Obias,
G. A. Noskin,
K. Englund,
M. A. Postelnick,
T. Suriano, and L. R. Peterson.
1998.
Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center.
Antimicrob. Agents Chemother.
42:734-738[Abstract/Free Full Text].
|
| 5.
|
Brawner, D. L., and J. E. Cutler.
1986.
Variability in expression of cell surface antigens of Candida albicans during morphogenesis.
Infect. Immun.
51:337-343[Abstract/Free Full Text].
|
| 6.
|
Brawner, D. L.,
J. E. Cutler, and W. L. Beatty.
1990.
Caveats in the investigation of form-specific molecules of Candida albicans.
Infect. Immun.
58:378-383[Abstract/Free Full Text].
|
| 7.
|
Casadevall, A.
1995.
Antibody immunity and invasive fungal infections.
Infect. Immun.
63:4211-4218[Medline].
|
| 8.
|
Casanova, M.,
M. L. Gil,
L. Cardeñoso,
J. P. Martínez, and R. Sentandreu.
1989.
Identification of wall-specific antigens synthesized during germ tube formation by Candida albicans.
Infect. Immun.
57:262-271[Abstract/Free Full Text].
|
| 9.
|
Casanova, M.,
J. L. López-Ribot,
C. Monteagudo,
A. Llombart-Bosch,
R. Sentandreu, and J. P. Martínez.
1992.
Identification of a 58-kilodalton cell surface fibrinogen-binding mannoprotein from Candida albicans.
Infect. Immun.
60:4221-4229[Abstract/Free Full Text].
|
| 10.
|
Cassone, A.
1989.
Cell wall of Candida albicans: its functions and its impact on the host.
Curr. Top. Med. Mycol.
3:248-314[Medline].
|
| 11.
|
Chaffin, W. L.,
J. L. López-Ribot,
M. Casanova,
D. Gozalbo, and J. P. Martinez.
1998.
Cell wall proteins of Candida albicans: identity, function, and expression.
Microbiol. Mol. Biol. Rev.
62:130-180.
[Abstract/Free Full Text] |
| 12.
|
Cutler, J. E., and T. Kanbe.
1993.
Antigenic variability of Candida albicans cell surface.
Curr. Top. Med. Mycol.
5:27-47[Medline].
|
| 13.
|
De Bernardis, F.,
A. Molinari,
M. Boccanera,
A. Stringaro,
R. Robert,
J. M. Senet,
G. Arancia, and A. Cassone.
1994.
Modulation of cell surface associated mannoprotein antigen expression in experimental candidal vaginitis.
Infect. Immun.
62:509-519[Abstract/Free Full Text].
|
| 14.
|
Dubois, M.,
K. A. Gilles,
J. K. Hamilton,
P. A. Rebers, and F. Smith.
1956.
Colorimetric method for determination of sugars and related substances.
Anal. Chem.
28:350-356.
|
| 15.
|
Franklyn, K. M.,
J. R. Warmington,
A. K. Ott, and R. B. Ashman.
1990.
An immunodominant antigen of Candida albicans shows homology to the enzyme enolase.
Immunol. Cell Biol.
68:173-178.
|
| 16.
|
Gil, M. L.,
M. Casanova,
J. P. Martínez, and R. Sentandreu.
1991.
Antigenic cell wall mannoproteins in Candida albicans isolates and other Candida species.
J. Gen. Microbiol.
137:1053-1056[Medline].
|
| 17.
|
Han, Y., and J. E. Cutler.
1995.
Antibody response that protects against disseminated candidiasis.
Infect. Immun.
63:2714-2719[Abstract].
|
| 18.
|
Hazen, K. C., and B. W. Hazen.
1992.
Hydrophobic surface protein masking by the opportunistic fungal pathogen Candida albicans.
Infect. Immun.
60:1499-1508[Abstract/Free Full Text].
|
| 19.
|
Hernando, F. L.,
J. C. Cailliez,
P. A. Trinel,
C. Faille,
D. W. R. Mackenzie, and D. Poulain.
1993.
Qualitative and quantitative differences in recognition patterns of Candida albicans protein and polysaccharide antigens by human sera.
J. Med. Vet. Mycol.
31:219-226[Medline].
|
| 20.
|
Hernando, F. L.,
J. J. Estevez,
M. Cebrian,
D. Poulain, and J. Pontón.
1993.
Identification of Candida albicans cell wall antigens lost during subculture in synthetic media.
J. Med. Vet. Mycol.
31:227-237[Medline].
|
| 21.
|
Jones, J. M.
1990.
Laboratory diagnosis of invasive candidiasis.
Clin. Microbiol. Rev.
3:32-45[Abstract/Free Full Text].
|
| 22.
|
Klein, R. S.,
C. A. Harris,
C. Butkus Small,
B. Moll,
M. Lesser, and G. H. Friendland.
1984.
Oral candidiasis as the initial manifestation of the acquired immunodeficiency syndrome.
N. Engl. J. Med.
311:354-357[Abstract].
|
| 23.
|
La Valle, R.,
C. Bromuro,
L. Ranucci,
H. M. Muller,
A. Crisanti, and A. Cassone.
1995.
Molecular cloning and expression of a 70-kilodalton heat shock protein of Candida albicans.
Infect. Immun.
63:4039-4045[Abstract].
|
| 24.
|
Lee, K. L.,
M. R. Buckley, and C. Campbell.
1975.
An amino acid liquid synthetic medium for development of mycelial and yeast forms of Candida albicans.
Sabouraudia
13:148-153[Medline].
|
| 25.
|
López-Ribot, J. L.,
H. M. Alloush,
B. J. Masten, and W. L. Chaffin.
1996.
Evidence for presence in the cell wall of Candida albicans of a protein related to the hsp70 family.
Infect. Immun.
64:3333-3340[Abstract].
|
| 26.
|
López-Ribot, J. L.,
M. Casanova,
M. L. Gil, and J. P. Martínez.
1996.
Common and form-specific cell wall antigens of Candida albicans as released by chemical and enzymatic treatments.
Mycopathologia
64:5239-5247.
|
| 27.
|
López-Ribot, J. L., and W. L. Chaffin.
1994.
Binding of the extracellular matrix component entactin to Candida albicans.
Infect. Immun.
62:4564-4571[Abstract/Free Full Text].
|
| 28.
|
López-Ribot, J. L.,
R. K. McAtee,
L. N. Lee,
W. R. Kirkpatrick,
T. C. White,
D. Sanglard, and T. F. Patterson.
1998.
Distinct patterns of gene expression associated with the development of fluconazole resistance in serial Candida albicans isolates from HIV-infected patients with oropharyngeal candidiasis.
Antimicrob. Agents Chemother.
42:2932-2937[Abstract/Free Full Text].
|
| 29.
|
López-Ribot, J. L.,
C. Monteagudo,
P. Sepúlveda,
M. Casanova, and W. L. Chaffin.
1996.
Expression of the fibrinogen binding mannoprotein and the laminin receptor of Candida albicans in vitro and in infected tissues.
FEMS Microbiol. Lett.
142:117-122[Medline].
|
| 30.
|
Marot-Lebond, A.,
R. Robert,
J. Aubry,
P. Ezcurra, and J. M. Senet.
1993.
Identification and immunochemical characterization of a germ tube specific antigen of Candida albicans.
FEMS Immunol. Med. Microbiol.
7:175-186[Medline].
|
| 31.
|
Marr, K. A.,
T. C. White,
J.-A. H. van Burik, and R. A. Bowden.
1997.
Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation.
Clin. Infect. Dis.
25:908-910[Medline].
|
| 32.
|
Martínez, J. P.,
M. L. Gil,
J. L. López-Ribot, and W. L. Chaffin.
1998.
Serologic response to cell wall proteins and mannoproteins of Candida albicans.
Clin. Microbiol. Rev.
11:121-141[Abstract/Free Full Text].
|
| 33.
|
Matthews, R. C.
1994.
Pathogenicity determinants of Candida albicans: potential targets for immunotherapy?
Microbiology
140:1505-1511[Medline].
|
| 34.
|
Matthews, R. C., and J. P. Burnie.
1992.
The role of hsp90 in fungal infection.
Immunol. Today
13:345-348[Medline].
|
| 35.
|
Matthews, R. C., and J. P. Burnie.
1996.
Antibodies against Candida: potential therapeutics?
Trends Microbiol.
4:354-358[Medline].
|
| 36.
|
National Committee for Clinical Laboratory Standards.
1997.
Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A.
National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 37.
|
Patterson, T. F.,
W. R. Kirkpatrick,
S. G. Revankar,
R. K. McAtee,
A. W. Fothergill,
D. I. McCarthy, and M. G. Rinaldi.
1996.
Comparative evaluation of macrodilution and chromogenic agar screening for determining fluconazole susceptibility of Candida albicans.
J. Clin. Microbiol.
34:3237-3239[Abstract].
|
| 38.
|
Patterson, T. F.,
S. G. Revankar,
W. R. Kirkpatrick,
O. Dib,
A. W. Fothergill,
S. W. Redding,
D. A. McGough, and M. G. Rinaldi.
1996.
A simple method for detecting fluconazole resistant yeast with chromogenic agar.
J. Clin. Microbiol.
34:1794-1797[Abstract].
|
| 39.
|
Pfaller, M. A.
1992.
The use of molecular techniques for epidemiologic typing of Candida species.
Curr. Top. Med. Mycol.
4:43-63[Medline].
|
| 40.
|
Pontón, J., and J. M. Jones.
1986.
Analysis of cell wall extracts of Candida albicans by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blot techniques.
Infect. Immun.
53:565-572[Abstract/Free Full Text].
|
| 41.
|
Pontón, J.,
A. Marot-Leblond,
P. A. Ezkurra,
B. Barturen,
R. Robert, and J. M. Senet.
1993.
Characterization of Candida albicans cell wall antigens with monoclonal antibodies.
Infect. Immun.
61:4842-4847[Abstract/Free Full Text].
|
| 42.
|
Poulain, D.,
V. Hopwood, and A. Vernes.
1985.
Antigenic variability of Candida albicans.
Crit. Rev. Microbiol.
12:223-270[Medline].
|
| 43.
|
Quindós, G.,
J. Pontón,
R. Cisterna, and D. W. Mackenzie.
1990.
Value of detection of antibodies to Candida albicans germ tube in the diagnosis of systemic candidiasis.
Eur. J. Clin. Microbiol. Infect. Dis.
9:178-183[Medline].
|
| 44.
|
Revankar, S. G.,
W. R. Kirkpatrick,
R. McAtee,
O. P. Dib,
A. W. Fothergill,
S. W. Redding,
D. A. McGough,
M. G. Rinaldi, and T. F. Patterson.
1996.
Detection and significance of fluconazole resistance in oropharyngeal candidiasis.
J. Infect. Dis.
174:821-827[Medline].
|
| 45.
|
Rex, J. H.,
M. G. Rinaldi, and M. A. Pfaller.
1995.
Resistance of Candida species to fluconazole.
Antimicrob. Agents Chemother.
39:1-8[Medline].
|
| 46.
|
Sundstrom, P. M., and G. R. Aliaga.
1992.
Molecular cloning of cDNA and analysis of protein secondary structure of Candida albicans enolase, an abundant, immunodominant glycolytic enzyme.
J. Bacteriol.
174:6789-6799[Abstract/Free Full Text].
|
| 47.
|
Sundstrom, P. M., and G. R. Aliaga.
1994.
A subset of proteins found in culture supernatants of Candida albicans includes the abundant, immunodominant, glycolytic enzyme enolase.
J. Infect. Dis.
169:452-456[Medline].
|
| 48.
|
Sundstrom, P. M.,
J. Jensen, and E. Balish.
1994.
Humoral and cellular responses to enolase after alimentary tract colonization or intravenous immunization with Candida albicans.
J. Infect. Dis.
170:390-395[Medline].
|
| 49.
|
Sundstrom, P. M.,
M. R. Tam,
E. J. Nichols, and G. E. Kenny.
1988.
Antigenic differences in the surface mannoproteins of Candida albicans as revealed by monoclonal antibodies.
Infect. Immun.
56:601-606[Abstract/Free Full Text].
|
| 50.
|
Tronchin, G.,
J. P. Bouchara, and R. Robert.
1989.
Dynamic changes of the cell wall surface of Candida albicans associated with germination and adherence.
Eur. J. Cell Biol.
50:285-290[Medline].
|
Clinical and Diagnostic Laboratory Immunology, September 1999, p. 665-670, Vol. 6, No. 5
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Angiolella, L., Micocci, M. M., D'Alessio, S., Girolamo, A., Maras, B., Cassone, A.
(2002). Identification of Major Glucan-Associated Cell Wall Proteins of Candida albicans and Their Role in Fluconazole Resistance. Antimicrob. Agents Chemother.
46: 1688-1694
[Abstract]
[Full Text]
-
Viudes, A., Perea, S., Lopez-Ribot, J. L.
(2001). Identification of Continuous B-Cell Epitopes on the Protein Moiety of the 58-Kilodalton Cell Wall Mannoprotein of Candida albicans Belonging to a Family of Immunodominant Fungal Antigens. Infect. Immun.
69: 2909-2919
[Abstract]
[Full Text]